CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −128,065 | $52.97 | $6.8M | 548,556 |
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −37,270 | $54.20 | $2.0M | 511,286 |
| 2026-10-15 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −78,400 | $55.02 | $4.3M | 432,886 |
| 2026-09-17 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −8,282 | $65.07 | $539K | 117,066 |
| 2026-09-17 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −101,691 | $64.59 | $6.6M | 439,688 |
| 2026-09-17 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −6,802 | $64.95 | $442K | 432,886 |
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −93,604 | $63.25 | $5.9M | 196,179 |
| 2026-09-16 | Heerma Peter EVP, CHIEF COMMERCIAL OFFICER | Sale 10b5-1 | −79,113 | $63.65 | $5.0M | 117,066 |
| 2026-09-16 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −99,716 | $63.26 | $6.3M | 529,011 |
| 2026-09-16 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −96,125 | $63.64 | $6.1M | 432,886 |
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −65,104 | $63.12 | $4.1M | 145,943 |
| 2026-09-16 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −47,746 | $63.61 | $3.0M | 98,197 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −27,473 | $62.00 | $1.7M | 110,543 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −20,735 | $62.61 | $1.3M | 89,808 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,900 | $63.69 | $121K | 87,908 |
| 2026-09-15 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −400 | $65.31 | $26K | 87,508 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −25,390 | $62.02 | $1.6M | 119,775 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −17,284 | $62.62 | $1.1M | 102,491 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −1,600 | $63.69 | $102K | 100,891 |
| 2026-09-15 | Inrig Jula EVP, Head of R&D & CMO | Sale 10b5-1 | −400 | $65.31 | $26K | 100,491 |
Page 1 of 22 · 429 trades